Antibodies and gene therapy: Teaching old 'magic bullets' new tricks

Trends in Immunology

Volumn 25, Issue 2, 2004, Pages 85-91

  Sanz, Laura ^a   Blanco, Belén ^b   Álvarez Vallina, Luis ^b  

^a MAYO CLINIC   (United States)

^b HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; CARCINOEMBRYONIC ANTIGEN; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; PROTEIN TYROSINE KINASE;

ANTIBODY AFFINITY; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIGEN BINDING; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CELL STRAIN; CELL SURVIVAL; CHIMERA; COMPLEMENTARITY DETERMINING REGION; CYTOKINE RELEASE; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; GENETIC ENGINEERING; HUMAN; HYBRIDOMA; IMMUNOGENICITY; LYMPHOCYTE PROLIFERATION; MAJOR HISTOCOMPATIBILITY COMPLEX; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PURIFICATION; REVIEW; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; TARGET CELL; TUMOR GROWTH; TUMOR VOLUME; XENOGRAFT;

EID: 0842303168     PISSN: 14714906     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.it.2003.12.001     Document Type: Review

References (72)

1. Carter P. Improving the efficacy of antibody-based cancer therapies. Nat. Rev. Cancer. 1:2001;118-129.
2. Kohler G., Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 256:1975;495-497.
3. Hudson P.J., Souriau C. Engineered antibodies. Nat. Med. 9:2003;129-134.
4. Jain R.K., Baxter L.T. Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: significance of elevated interstitial pressure. Cancer Res. 48:1988;7022-7032.
5. Noel D., et al. High in vivo production of a model monoclonal antibody on adenoviral gene transfer. Hum. Gene Ther. 13:2002;1483-1493.
6. Noel D., et al. In vitro and in vivo secretion of cloned antibodies by genetically modified myogenic cells. Hum. Gene Ther. 8:1997;1219-1229.
7. Whittington H.A., et al. Recombinant adenoviral delivery for in vivo expression of scFv antibody fusion proteins. Gene Ther. 5:1998;770-777.
8. Arafat W.O., et al. Effective single chain antibody (scFv) concentrations in vivo via adenoviral vector mediated expression of secretory scFv. Gene Ther. 9:2002;256-262.
9. Sanz L., Alvarez-Vallina L. The extracellular matrix: a new turn-of-the-screw for anti-angiogenic strategies. Trends Mol. Med. 9:2003;256-262.
10. Sanz L., et al. Single-chain antibody-based gene therapy: inhibition of tumor growth by in situ production of phage-derived human antibody fragments blocking functionally active sites of cell-associated matrices. Gene Ther. 9:2002;1049-1053.
11. Afanasieva T.A., et al. Single-chain antibody and its derivatives directed against vascular endothelial growth factor: application for antiangiogenic gene therapy. Gene Ther. 10:2003;1850-1859.
12. Segal D.M., et al. Bispecific antibodies in cancer therapy. Curr. Opin. Immunol. 11:1999;558-562.
13. Perez P., et al. Specific targeting of cytotoxic T cells by anti-T3 linked to anti-target cell antibody. Nature. 316:1985;354-356.
14. Deo Y.M., et al. Clinical significance of IgG Fc receptors and FcγR-directed immunotherapies. Immunol. Today. 18:1997;127-135.
15. Daniel P.T., et al. Immunotherapy of B-cell lymphoma with CD3x19 bispecific antibodies: costimulation via CD28 prevents 'veto' apoptosis of antibody-targeted cytotoxic T cells. Blood. 92:1998;4750-4757.
16. Guyre P.M., et al. Monoclonal antibodies that bind to distinct epitopes on FcγRI are able to trigger receptor function. J. Immunol. 143:1989;1650-1655.
17. Deo Y.M., et al. Bispecific molecules directed to the Fc receptor for IgA (FcαRI, CD89) and tumor antigens efficiently promote cell-mediated cytotoxicity of tumor targets in whole blood. J. Immunol. 160:1998;1677-1686.
18. Eshhar Z., et al. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the γ or ζ subunits of the immunoglobulin and T-cell receptors. Proc. Natl. Acad. Sci. U. S. A. 90:1993;720-724.
19. Nolan K.F., et al. Bypassing immunization: optimized design of 'designer T cells' against carcinoembryonic antigen (CEA)-expressing tumors, and lack of suppression by soluble CEA. Clin. Cancer Res. 5:1999;3928-3941.
20. Brocker T., et al. Redirecting the complete T cell receptor/CD3 signaling machinery towards native antigen via modified T cell receptor. Eur. J. Immunol. 26:1996;1770-1774.
21. Fitzer-Attas C.J., et al. Harnessing Syk family tyrosine kinases as signaling domains for chimeric single chain of the variable domain receptors: optimal design for T cell activation. J. Immunol. 160:1998;145-154.
22. Álvarez-Vallina L., Hawkins R.E. Antigen-specific targeting of CD28-mediated T cell co-stimulation using chimeric single-chain antibody variable fragment-CD28 receptors. Eur. J. Immunol. 26:1996;2304-2309.
23. Finney H.M., et al. Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product. J. Immunol. 161:1998;2791-2797.
24. Geiger T.L., et al. Integrated src kinase and costimulatory activity enhances signal transduction through single-chain chimeric receptors in T lymphocytes. Blood. 98:2001;2364-2371.
25. Blanco B., et al. Induction of human T lymphocyte cytotoxicity and inhibition of tumor growth by tumor-specific diabody-based molecules secreted from gene-modified bystander cells. J. Immunol. 171:2003;1070-1077.
26. Hayden M.S., et al. Single-chain mono- and bispecific antibody derivatives with novel biological properties and antitumour activity from a COS cell transient expression system. Ther. Immunol. 1:1994;3-15.
27. Mack M., et al. A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity. Proc. Natl. Acad. Sci. U. S. A. 92:1995;7021-7025.
28. De Jonge J., et al. In vivo retargeting of T cell effector function by recombinant bispecific single chain Fv (anti-CD3 x anti-idiotype) induces long-term survival in the murine BCL1 lymphoma model. J. Immunol. 161:1998;1454-1461.
29. McCall A.M., et al. Isolation and characterization of an anti-CD16 single-chain Fv fragment and construction of an anti-HER2/neu/anti-CD16 bispecific scFv that triggers CD16-dependent tumor cytolysis. Mol. Immunol. 36:1999;433-445.
30. Brüsselbach T., et al. Enzyme recruitment and tumor cell killing in vitro by a secreted bispecific single-chain diabody. Tumor Targeting. 4:1999;115-123.
31. Alt M., et al. Novel tetravalent and bispecific IgG-like antibody molecules combining single-chain diabodies with the immunoglobulin γ1 Fc or CH3 region. FEBS Lett. 454:1999;90-94.
32. Loffler A., et al. A recombinant bispecific single-chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes. Blood. 95:2000;2098-2103.
33. Wuest T., et al. Construction of a bispecific single chain antibody for recruitment of cytotoxic T cells to the tumour stroma associated antigen fibroblast activation protein. J. Biotechnol. 92:2001;159-168.
34. Gross G., et al. Chimaeric T-cell receptors specific to a B-lymphoma idiotype: a model for tumour immunotherapy. Biochem. Soc. Trans. 23:1995;1079-1082.
35. Sadelain M., et al. Targeting tumours with genetically enhanced T lymphocytes. Nat. Rev. Cancer. 3:2003;35-45.
36. Jensen M., et al. CD20 is a molecular target for scFvFc:ζ receptor redirected T cells: implications for cellular immunotherapy of CD20+ malignancy. Biol. Blood Marrow Transplant. 4:1998;75-83.
37. Hombach A., et al. An anti-CD30 chimeric receptor that mediates CD3-ζ-independent T-cell activation against Hodgkin's lymphoma cells in the presence of soluble CD30. Cancer Res. 58:1998;1116-1119.
38. Hekele A., et al. Growth retardation of tumors by adoptive transfer of cytotoxic T lymphocytes reprogrammed by CD44v6-specific scFv:ζ-chimera. Int. J. Cancer. 68:1996;232-238.
39. Ren-Heidenreich L., et al. Comparison of the TCR ζ-chain with the FcRγ-chain in chimeric TCR constructs for T cell activation and apoptosis. Cancer Immunol. Immunother. 51:2002;417-423.
40. Royal R.E., et al. Enzyme recruitment and tumor cell killing in vitro a chimeric T-cell receptor. Proc. Am. Assoc. Cancer Res. 37:1996;481.
41. Stancovski I., et al. Targeting of T lymphocytes to Neu/HER2-expressing cells using chimeric single chain Fv receptors. J. Immunol. 151:1993;6577-6582.
42. Hwu P., et al. Lysis of ovarian cancer cells by human lymphocytes redirected with a chimeric gene composed of an antibody variable region and the Fc receptor γ chain. J. Exp. Med. 178:1993;361-366.
43. Weijtens M.E., et al. Single chain Ig/γ gene-redirected human T lymphocytes produce cytokines, specifically lyse tumor cells, and recycle lytic capacity. J. Immunol. 157:1996;836-843.
44. Reinhold U., et al. Specific lysis of melanoma cells by receptor grafted T cells is enhanced by anti-idiotypic monoclonal antibodies directed to the scFv domain of the receptor. J. Invest. Dermatol. 112:1999;744-750.
45. Kershaw M.H., et al. Generation of gene-modified T cells reactive against the angiogenic kinase insert domain-containing receptor (KDR) found on tumor vasculature. Hum. Gene Ther. 11:2000;2445-2452.
46. Gong M.C., et al. Cancer patient T cells genetically targeted to prostate-specific membrane antigen specifically lyse prostate cancer cells and release cytokines in response to prostate-specific membrane antigen. Neoplasia. 1:1999;123-127.
47. + tumor cells by a chimeric receptor with antibody-like specificity for a carbohydrate epitope. Gastroenterology. 113:1997;1163-1170.
48. Darcy P.M., et al. Redirected perforin-dependent lysis of colon carcinoma by ex vivo genetically engineered CTL. J. Immunol. 164:2000;3705-3712.
49. Álvarez-Vallina L. Genetic approaches for antigen-selective cell therapy. Curr. Gene Ther. 1:2001;385-397.
50. Abken H., et al. Tuning tumor-specific T-cell activation: a matter of costimulation? Trends Immunol. 23:2002;240-245.
51. Griffin M.D., et al. Development and applications of surface-linked single chain antibodies against T-cell antigens. J. Immunol. Methods. 248:2001;77-90.
52. Winberg G., et al. Surface expression of CD28 single chain Fv for costimulation by tumor cells. Immunol. Rev. 153:1996;209-223.
53. Melero I., et al. Amplification of tumor immunity by gene transfer of the co-stimulatory 4-1BB ligand: synergy with the CD28 co-stimulatory pathway. Eur. J. Immunol. 28:1998;1116-1121.
54. Marasco W.A. Intrabodies: turning the humoral immune system outside in for intracellular immunization. Gene Ther. 4:1997;11-15.
55. Deshane J., et al. Targeted tumor killing via an intracellular antibody against erbB-2. J. Clin. Invest. 96:1995;2980-2989.
56. Alvarez R.D., et al. A cancer gene therapy approach utilizing an anti-erbB-2 single-chain antibody-encoding adenovirus (AD21): a phase I trial. Clin. Cancer Res. 6:2000;3081-3087.
57. Jannot C.B., et al. Intracellular expression of a single-chain antibody directed to the EGFR leads to growth inhibition of tumor cells. Oncogene. 13:1996;275-282.
58. Piche A., et al. Modulation of Bcl-2 protein levels by an intracellular anti-Bcl-2 single-chain antibody increases drug-induced cytotoxicity in the breast cancer cell line MCF-7. Cancer Res. 58:1998;2134-2140.
59. Jendreyko, N. et al. Intra-diabodies: bispecific, tetravalent antibodies for the simultaneous functional knockout of two cell surface receptors. J. Biol. Chem. (in press).
60. Hyland S., et al. Generation and functional characterization of intracellular antibodies interacting with the kinase domain of human EGF receptor. Oncogene. 22:2003;1557-1567.
61. Cochet O., et al. Intracellular expression of an antibody fragment-neutralizing p21 ras promotes tumor regression. Cancer Res. 58:1998;1170-1176.
62. Tanaka T., Rabbitts T.H. Intrabodies based on intracellular capture frameworks that bind the RAS protein with high affinity and impair oncogenic transformation. EMBO J. 22:2003;1025-1035.
63. Dauvillier S., et al. Intracellular single-chain variable fragments directed to the Src homology 2 domains of Syk partially inhibit Fcε RI signaling in the RBL-2H3 cell line. J. Immunol. 169:2002;2274-2283.
64. Tse E., et al. Intracellular antibody capture technology: application to selection of intracellular antibodies recognising the BCR-ABL oncogenic protein. J. Mol. Biol. 317:2002;85-94.
65. Heike Y., et al. Overcoming multi-drug resistance using an intracellular anti-MDR1 sFv. Int. J. Cancer. 92:2001;115-122.
66. Tse E., Rabbitts T.H. Intracellular antibody-caspase-mediated cell killing: an approach for application in cancer therapy. Proc. Natl. Acad. Sci. U. S. A. 97:2000;12266-12271.
67. Strube R.W., Chen S.Y. Characterization of anti-cyclin E single-chain Fv antibodies and intrabodies in breast cancer cells: enhanced intracellular stability of novel sFv-F(c) intrabodies. J. Immunol. Methods. 263:2002;149-167.
68. Caron de Fromentel C., et al. Restoration of transcriptional activity of p53 mutants in human tumour cells by intracellular expression of anti-p53 single chain Fv fragments. Oncogene. 18:1999;551-557.
69. Cohen P.A., et al. Characterization of a new intrabody directed against the N-terminal region of human p53. Oncogene. 17:1998;2445-2456.
70. Kasono K., et al. Tetracycline-induced expression of an anti-c-Myb single-chain antibody and its inhibitory effect on proliferation of the human leukemia cell line K562. Cancer Gene Ther. 7:2000;151-159.
71. Cattaneo A., Biocca S. The selection of intracellular antibodies. Trends Biotechnol. 17:1999;115-121.
72. Visintin M., et al. The intracellular antibody capture technology (IACT): towards a consensus sequence for intracellular antibodies. J. Mol. Biol. 317:2002;73-83.